Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Use of Anti-CD40 mAb in Cancer.
Remer M, White A, Glennie M, Al-Shamkhani A, Johnson P. Remer M, et al. Among authors: white a, al shamkhani a. Curr Top Microbiol Immunol. 2017;405:165-207. doi: 10.1007/82_2014_427. Curr Top Microbiol Immunol. 2017. PMID: 25651948 Review.
FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.
White AL, Chan HT, French RR, Beers SA, Cragg MS, Johnson PW, Glennie MJ. White AL, et al. Cancer Immunol Immunother. 2013 May;62(5):941-8. doi: 10.1007/s00262-013-1398-6. Epub 2013 Mar 31. Cancer Immunol Immunother. 2013. PMID: 23543215 Free PMC article. Review.
Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.
White AL, Dou L, Chan HT, Field VL, Mockridge CI, Moss K, Williams EL, Booth SG, French RR, Potter EA, Butts C, Al-Shamkhani A, Cragg MS, Verbeek JS, Johnson PW, Glennie MJ, Beers SA. White AL, et al. Among authors: al shamkhani a. J Immunol. 2014 Aug 15;193(4):1828-35. doi: 10.4049/jimmunol.1303204. Epub 2014 Jul 14. J Immunol. 2014. PMID: 25024386
Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.
White AL, Chan HT, French RR, Willoughby J, Mockridge CI, Roghanian A, Penfold CA, Booth SG, Dodhy A, Polak ME, Potter EA, Ardern-Jones MR, Verbeek JS, Johnson PW, Al-Shamkhani A, Cragg MS, Beers SA, Glennie MJ. White AL, et al. Among authors: al shamkhani a. Cancer Cell. 2015 Jan 12;27(1):138-48. doi: 10.1016/j.ccell.2014.11.001. Epub 2014 Dec 11. Cancer Cell. 2015. PMID: 25500122 Free PMC article.
Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.
Yu X, Chan HTC, Orr CM, Dadas O, Booth SG, Dahal LN, Penfold CA, O'Brien L, Mockridge CI, French RR, Duriez P, Douglas LR, Pearson AR, Cragg MS, Tews I, Glennie MJ, White AL. Yu X, et al. Among authors: white al. Cancer Cell. 2018 Apr 9;33(4):664-675.e4. doi: 10.1016/j.ccell.2018.02.009. Epub 2018 Mar 22. Cancer Cell. 2018. PMID: 29576376 Free PMC article.
Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity.
Yu X, Chan HTC, Fisher H, Penfold CA, Kim J, Inzhelevskaya T, Mockridge CI, French RR, Duriez PJ, Douglas LR, English V, Verbeek JS, White AL, Tews I, Glennie MJ, Cragg MS. Yu X, et al. Among authors: white al. Cancer Cell. 2020 Jun 8;37(6):850-866.e7. doi: 10.1016/j.ccell.2020.04.013. Epub 2020 May 21. Cancer Cell. 2020. PMID: 32442402 Free PMC article.
133 results